Navigation Links
Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
Date:3/7/2013

SAN DIEGO, March 7, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the full year and fourth quarter ended December 31, 2012, on Wednesday, March 13, 2013 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time).

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 34404715. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.

McDavid Stilwell
Vice President, Corporate Communications & Business Development
+1-858-875-8600


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
2. Orexigen Therapeutics to Present at Upcoming Investor Conferences
3. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
4. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
5. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
6. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
7. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
8. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
9. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
10. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
11. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... Research and Markets has announced the addition of the ... Application, Usability - Forecast to 2025" report to their offering. ... , , ... grow at a CAGR of around 3.2% from 2015 to 2025. ... advancements in extracellular microelectrode arrays and intracellular microelectrodes, research in left-to-right ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... ... announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input to ... Medical Informatics . , Results of the comparative usability study demonstrate that a ...
(Date:12/8/2016)... ... 2016 , ... With the increasing demand for dental implants, the National Association ... to inform dentists and patients about the safety issues related to dental restorations. According ... the U.S. is projected to reach $6.4 billion in 2018 with more than 30 ...
(Date:12/8/2016)... ... 08, 2016 , ... Launching of the ... Instance Manager architecture, meeting the needs of multichannel growth and doubling the ... auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, administrative flexibility ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into ... claim in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th ... According to the study, medical payments per claim in California decreased 4 percent in ...
(Date:12/8/2016)... Rock, AR (PRWEB) , ... December 08, 2016 ... ... providing insurance and financial planning services from offices headquartered in Little Rock, has ... Food Pantry. , According to the National Foundation to End Senior Hunger, Arkansas ...
Breaking Medicine News(10 mins):